Wave Life Sciences Ltd. (WVE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing RNA medicines using its proprietary PRISM platform. The company targets rare and common disorders including obesity, alpha-1 antitrypsin deficiency (AATD), Duchenne muscular dystrophy (DMD), and Huntington's disease (HD). This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $8.7 million | $19.7 million | $17.9 million | $32.2 million |
| Net Loss | $(50.5) million | $(32.9) million | $(97.3) million | $(64.5) million |
| Operating Expenses | $61.5 million | $54.7 million | $120.4 million | $101.7 million |
| Cash & Equivalents (End of Period) | $208.5 million (as of June 30, 2025) | |||
| Accumulated Deficit | ||||
| Net Cash Used in Operating Activities | N/A (Quarterly) | $(109.1) million | $(60.9) million |
Note: The company has no product revenue; all revenue is derived from collaboration agreements, primarily with GSK.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 56% year-over-year in Q2 2025 ($8.7M vs. $19.7M). This was driven by a decrease in revenue recognized under the GSK Collaboration Agreement and the expiration of the Takeda Collaboration Agreement in October 2024.
- Increased Loss: Net loss widened to $50.5 million in Q2 2025 from $32.9 million in Q2 2024, primarily due to higher operating expenses and lower revenue.
- Expense Growth: Total operating expenses increased by $6.8 million ($61.5M vs. $54.7M). Research and Development (R&D) expenses rose $3.1 million, driven by a $6.8 million increase in "Other R&D" (platform development and compensation) and increased spending on the obesity program (INHBE), partially offset by decreases in AATD, DMD, and HD program costs.
- Liquidity: Cash and cash equivalents decreased from $302.1 million at year-end 2024 to $208.5 million at June 30, 2025, reflecting a net cash burn of $93.6 million over the six-month period.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash resources ($208.5 million) to fund operations for at least the next twelve months. Subsequent to the quarter-end, the company raised an additional $24.9 million via its "at-the-market" equity program.
- Clinical Milestones:
- Obesity (WVE-007): Dosing complete in Cohort 2 (240 mg) of the INLIGHT Phase 1 trial; Cohort 3 (400 mg) dosing underway. Data expected Q4 2025.
- AATD (WVE-006): Positive proof-of-mechanism data announced. Data from 200 mg cohorts expected Q3 2025; 400 mg data expected Fall 2025.
- DMD (WVE-N531): Positive 48-week data from FORWARD-53 trial. FDA confirmed accelerated approval pathway remains open. NDA filing planned for 2026.
- HD (WVE-003): Positive Phase 1b/2a data. IND application for Phase 2/3 study expected in H2 2025.
- Risks: The company has never been profitable and expects to incur significant losses. Future funding may be required, which could dilute shareholders. Success depends on clinical trial outcomes, regulatory approvals, and the ability to raise capital. The company maintains a full valuation allowance on deferred tax assets.
Investor Verification Checklist
- Verify the timeline and data release dates for the WVE-007 (Obesity) and WVE-006 (AATD) clinical trials, as these are near-term catalysts.
- Monitor the "at-the-market" equity program activity and cash burn rate to assess runway beyond the stated 12-month horizon.
- Review the specific allocation of the $6.8 million increase in "Other R&D" expenses to understand platform investment vs. overhead.
- Confirm the status of the GSK Collaboration Agreement revenue recognition schedule and remaining deferred revenue ($55.8 million).
- Assess the impact of the Takeda collaboration expiration on the HD program's future funding and development strategy.